Skip to Main content Skip to Navigation
Journal articles

Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab

Abstract : Background: Alemtuzumab is a humanized monoclonal antibody directed at CD52 approved as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS). Objective: To describe a case of a life-threatening autoimmune anemia occurring after a first course of alemtuzumab for relapsing-remitting MS in a 28-year-old male. Methods: Case report. Results: A 28-year-old male developed a life-threatening autoimmune anemia occurring 11 months after first alemtuzumab course. Conclusion: We report the third case of autoimmune hemolytic anemia following treatment with alemtuzumab in a young MS patient. Due to the severity of this adverse event, neurologists using this treatment should be alert.
Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03538546
Contributor : Jean-Philippe RANJEVA Connect in order to contact the contributor
Submitted on : Friday, January 21, 2022 - 10:10:14 AM
Last modification on : Saturday, January 22, 2022 - 3:36:52 AM

Identifiers

Collections

Citation

Benoit Meunier, Audrey Rico, Julie Seguier, Clemence Boutiere, Mikael Ebbo, et al.. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. Multiple Sclerosis Journal, SAGE Publications, 2018, 24 (6), pp.811-813. ⟨10.1177/1352458517729766⟩. ⟨hal-03538546⟩

Share

Metrics

Record views

4